Zydus Cadila has received final approval from the US Food and Drug Administration (FDA) to market Glycopyrrolate injection in the strengths of 0.2 mg/mL and 0.4 mg/2 mL (0.2 mg/mL) single-dose vials and 1 mg/5 mL (0.2 mg/mL) and 4 mg/20 mL (0.2 mg/mL) multiple-dose vials, the company said in a statement yesterday.
It notified that Glycopyrrolate is used before surgery to decrease the volume of secretions from mouth, lungs and stomach. It can also be used either before or during surgery to maintain heart’s normal beating rhythm. It is also used to counter the effects of some other medicines, which can slow heartbeat or produce excessive secretions when used during surgery. Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastro-intestinal ulcer when rapid effect is desired or when oral medication is not tolerated. The drug will be manufactured at the group’s injectables’ manufacturing facility at CHL-Jarod, near Vadodara.